{"entity":{"id":"nct06480565","kind":"trial","name":"A Phase 1/2 Trial of ADI-270 in ccRCC","aka":[],"tldr":"A phase 1/2 trial of ADI-270, Fludarabine, Cyclophosphamide in renal cell carcinoma, run by Adicet Therapeutics, active and no longer recruiting.","summary":"A Phase 1/2 Trial of ADI-270 in ccRCC is a phase 1/2 interventional study registered as NCT06480565 by Adicet Therapeutics, with 60 participants planned, started 2024-12-12 and due to reach its primary completion in 2026-12. Interventions recorded: ADI-270, Fludarabine, Cyclophosphamide. Conditions listed: Clear Cell Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06480565","url":"https://clinicaltrials.gov/study/NCT06480565"}],"tags":["ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["adi-270","fludarabine","cyclophosphamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06480565","phase":"1/2","setting":"A Phase 1/2 Trial of ADI-270 (Engineered γδ Chimeric Receptor [CAR] Vδ1 T Cells Targeting CD70) in Adults With Relapsed or Refractory (R/R) Clear Cell Renal Cell Carcinoma (ccRCC)","sponsor":"Adicet Therapeutics","enrolled":60,"outcomes":[]},"route":"/trials/nct06480565/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"adi-270","kind":"drug","name":"ADI-270","route":"/drugs/adi-270/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/"}]}}